Evidence map›Paper›PMID 36711508›Full record

ArticlebioRxiv : the preprint server for biology2023

Rationally designed inhibitors of the Musashi protein-RNA interaction by hotspot mimicry.

Nan Bai, Yusuf Adeshina, Igor Bychkov, Yan Xia, Ragul Gowthaman, Sven A Miller, Abhishek K Gupta, David K Johnson, Lan Lan, Erica A Golemis and 5 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Nan BaiProgram in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia PA 19111.
Yusuf AdeshinaProgram in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia PA 19111.
Igor BychkovDivision of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.
Yan XiaDepartment of Molecular Biosciences, University of Kansas, Lawrence KS 66045.
Ragul GowthamanCenter for Computational Biology, University of Kansas, Lawrence KS 66045.
Sven A MillerProgram in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia PA 19111.
Abhishek K GuptaSection of Hematology, Yale Cancer Center, New Haven CT 06520.
David K JohnsonCenter for Computational Biology, University of Kansas, Lawrence KS 66045.
Lan LanDepartment of Molecular Biosciences, University of Kansas, Lawrence KS 66045.
Erica A GolemisProgram in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia PA 19111.
Petr B MakhovProgram in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia PA 19111.
Liang XuDepartment of Molecular Biosciences, University of Kansas, Lawrence KS 66045.
Manoj M PillaiSection of Hematology, Yale Cancer Center, New Haven CT 06520.
Yanis BoumberDivision of Hematology/Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611.
John KaranicolasProgram in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia PA 19111.
Fox Chase Cancer Center · USUniversity of Kansas · USNorthwestern University · USYale Cancer Center · US

Funding

Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Devalingam Mahalingam · 1993 to 2026
$153.9M
WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Eric Andrew Ross · 1985 to 2026
$138.8M
Designing selective kinase inhibitors via deep learningR01GM141513 · NIGMS · RESEARCH INST OF FOX CHASE CAN CTR · PI RINK, LORI · 2022 to 2025
$2.4M
Targeting Musashi-2 (MSI2) regulation of VEGFR2 / VEGF-A in lung cancerR01CA218802 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI BOUMBER, YANIS · 2018 to 2022
$1.9M
Robust Rational Design of Chemical Tools to Inhibit RNA-binding ProteinsR01GM123336 · NIGMS · RESEARCH INST OF FOX CHASE CAN CTR · PI KARANICOLAS, JOHN · 2017 to 2020
$1.5M
Small molecules modulating RNA-binding protein Msi1R01CA178831 · NCI · UNIVERSITY OF KANSAS LAWRENCE · PI NEUFELD, KRISTI L, XU, LIANG · 2014 to 2016
$1.3M
NCI NIH HHS P30 CA006927NCI NIH HHS P30 CA060553NCI NIH HHS R01 CA178831NCI NIH HHS R01 CA218802NIGMS NIH HHS R01 GM123336NIGMS NIH HHS R01 GM141513
6 · The paper itself

Abstract

RNA-binding proteins (RBPs) are key post-transcriptional regulators of gene expression, and thus underlie many important biological processes. Here, we developed a strategy that entails extracting a "hotspot pharmacophore" from the structure of a protein-RNA complex, to create a template for designing small-molecule inhibitors and for exploring the selectivity of the resulting inhibitors. We demonstrate this approach by designing inhibitors of Musashi proteins MSI1 and MSI2, key regulators of mRNA stability and translation that are upregulated in many cancers. We report this novel series of MSI1/MSI2 inhibitors is specific and active in biochemical, biophysical, and cellular assays. This study extends the paradigm of "hotspots" from protein-protein complexes to protein-RNA complexes, supports the "druggability" of RNA-binding protein surfaces, and represents one of the first rationally-designed inhibitors of non-enzymatic RNA-binding proteins. Owing to its simplicity and generality, we anticipate that this approach may also be used to develop inhibitors of many other RNA-binding proteins; we also consider the prospects of identifying potential off-target interactions by searching for other RBPs that recognize their cognate RNAs using similar interaction geometries. Beyond inhibitors, we also expect that compounds designed using this approach can serve as warheads for new PROTACs that selectively degrade RNA-binding proteins.

Identifiers

PMID36711508
PMCPMC9882015
OpenAlexW4315474756

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.